The global head and neck cancer market was valued at US$ 953.3 Mn in 2018 and is anticipated expand at a CAGR of 9.7% from 2019 to 2026. Growth of the pharmaceutical industry, government initiatives, increase in health care expenditure, surge in product approval, and rise in patient population are projected to augment the global market from 2019 to 2026. Cancers of the head and neck are categorized depending on the location. These areas include oral cavity, pharynx, larynx, paranasal sinuses & nasal cavity, and salivary glands. Increase in consumption of alcohol and tobacco is a major cause of head and neck cancer. An estimated 75% of head and neck cancers is caused due to consumption of alcohol and tobacco. Increase in the number of head and neck cancer patients across the world is anticipated to drive demand for therapeutics.
The report analyzes and forecasts the head and neck cancer market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of head and neck cancer, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major head and neck cancer companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of head and neck cancer upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of head and neck cancer and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global head and neck cancer market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the head and neck cancer market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of head and neck cancer market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles major players in the global head and neck cancer market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Sanofi, Pfizer, Eli Lilly and Company, Merck KgaA, Bristol-Myers Squibb Company, Bayer AG, Galera, Fresenius Kabi, and Teva Pharmaceuticals.
The global head and neck cancer market has been segmented as below:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Head and Neck Cancer (HNC) Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Head and Neck Cancer (HNC) Market Analysis and Forecasts, 2018–2026
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
6. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2018–2026
6.3.1. EGFR Inhibitors
6.3.2. Mitotic Inhibitors
6.3.3. Anti-PD-1 Monoclonal Antibodies
6.3.4. Others
6.4. Market Attractiveness by Drug Class
7. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2018–2026
7.3.1. Hospitals Pharmacies
7.3.2. Retail Pharmacies
7.3.3. E-commerce
7.4. Market Attractiveness, by Distribution Channel
8. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Head and Neck Cancer (HNC) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2018–2026
9.2.1. EGFR Inhibitors
9.2.2. Mitotic Inhibitors
9.2.3. Anti-PD-1 Monoclonal Antibodies
9.2.4. Others
9.3. Market Value Forecast, by Distribution Channel, 2018–2026
9.3.1. Hospitals Pharmacies
9.3.2. Retail Pharmacies
9.3.3. E-commerce
9.4. Market Value Forecast, by Country, 2018-2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Head and Neck Cancer (HNC) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2018–2026
10.2.1. EGFR Inhibitors
10.2.2. Mitotic Inhibitors
10.2.3. Anti-PD-1 Monoclonal Antibodies
10.2.4. Others
10.3. Market Value Forecast, by Distribution Channel, 2018–2026
10.3.1. Hospitals Pharmacies
10.3.2. Retail Pharmacies
10.3.3. E-commerce
10.4. Market Value Forecast, by Country/Sub-region, 2018–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Head and Neck Cancer (HNC) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2018–2026
11.2.1. EGFR Inhibitors
11.2.2. Mitotic Inhibitors
11.2.3. Anti-PD-1 Monoclonal Antibodies
11.2.4. Others
11.3. Market Value Forecast, by Distribution Channel, 2018–2026
11.3.1. Hospitals Pharmacies
11.3.2. Retail Pharmacies
11.3.3. E-commerce
11.4. Market Value Forecast, by Country/Sub-region, 2018–2026
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of APAC
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Head and Neck Cancer (HNC) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2018–2026
12.2.1. EGFR Inhibitors
12.2.2. Mitotic Inhibitors
12.2.3. Anti-PD-1 Monoclonal Antibodies
12.2.4. Others
12.3. Market Value Forecast, by Distribution Channel, 2018–2026
12.3.1. Hospitals Pharmacies
12.3.2. Retail Pharmacies
12.3.3. E-commerce
12.4. Market Value Forecast, by Country/Sub-region, 2018–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of LATAM
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Head and Neck Cancer (HNC) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2018–2026
13.2.1. EGFR Inhibitors
13.2.2. Mitotic Inhibitors
13.2.3. Anti-PD-1 Monoclonal Antibodies
13.2.4. Others
13.3. Market Value Forecast, by Distribution Channel, 2018–2026
13.3.1. Hospitals Pharmacies
13.3.2. Retail Pharmacies
13.3.3. E-commerce
13.4. Market Value Forecast, by Country/Sub-region, 2018–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company (2017)
14.3. Company Profiles
14.3.1. Sanofi
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Eli Lilly and Company
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. AstraZeneca
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Teva Pharmaceuticals
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. F. Hoffmann-La Roche Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Fresenius Kabi
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Merck
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Bayer AG
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Bristol-Myers Squibb Company
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Galera
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers